Decoy Therapeutics (FRA:FP11) Change In Inventory: €0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:FP11 Decoy Therapeutics Inc FRA:FP11
23 GF Score
Price €5.23
! 3 Warning Signs
View Full Analysis

What is Decoy Therapeutics Change In Inventory?

Decoy Therapeutics FRA:FP11 23 Change In Inventory is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:FP11 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Decoy Therapeutics's change in inventory for the quarter that ended in Jun. 2026 was €0.00 Mil. It means Decoy Therapeutics's inventory stayed the same from Mar. 2026 to Jun. 2026 .

Decoy Therapeutics's change in inventory for the fiscal year that ended in Dec. 2025 was €0.00 Mil. It means Decoy Therapeutics's inventory stayed the same from Dec. 2024 to Dec. 2025 .

Decoy Therapeutics's Total Inventories for the quarter that ended in Jun. 2026 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Decoy Therapeutics  (FRA:FP11) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Decoy Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0/0*365 / 4
=N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Decoy Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0 / 0
=N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Decoy Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Decoy Therapeutics Change In Inventory Related Terms

Decoy Therapeutics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Decoy Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Decoy Therapeutics Change In Inventory Chart

Decoy Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Decoy Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:FP11
23GF Score
Decoy Therapeutics Inc FRA:FP11
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Decoy Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €0.00 Mil mean?
Decoy Therapeutics (FRA:FP11) has a Change In Inventory of €0.00 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Decoy Therapeutics and its competitors.
Is Decoy Therapeutics' Change In Inventory too high?
Decoy Therapeutics' current Change In Inventory is €0.00 Mil. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' Change In Inventory compare to PKTX and CASIF?
Decoy Therapeutics' Change In Inventory of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Decoy Therapeutics and its competitors. Decoy Therapeutics's current Change In Inventory is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (FRA:FP11) has a current Change In Inventory of €0.00 Mil. The current Change In Inventory is €0.00 Mil. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Decoy Therapeutics (FRA:FP11), the current Change In Inventory is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Decoy Therapeutics Business Description

Other Exchanges DCOY:USA
Address 2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score

Get the complete analysis for FRA:FP11

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price